Mouse Monoclonal CA9 Antibody

+ +

•  

   
     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

•  

   
     Western blot analysis using CA9 mouse mAb against A431 (1) and SW620 (2) cell lysate.    

•  

   
     Flow cytometric analysis of NTERA-2 cells using CA9 mouse mAb (green) and negative control (red).    

Carbonic anhydrase IX (CA9) is a transmembrane enzyme involved in pH regulation and cellular response to hypoxia. It is encoded by the *CA9* gene and is primarily regulated by hypoxia-inducible factor-1α (HIF-1α) under low-oxygen conditions. CA9 plays a critical role in tumor biology by maintaining intracellular pH balance, promoting cell survival, and facilitating metastasis in hypoxic microenvironments. Overexpression of CA9 is strongly associated with various cancers, particularly clear cell renal cell carcinoma (ccRCC), where it serves as a diagnostic and prognostic biomarker.

CA9 antibodies are immunological tools designed to detect and quantify CA9 protein expression in research and clinical settings. These antibodies enable the study of CA9's functional role in tumor progression, hypoxia adaptation, and resistance to therapies. Clinically, CA9-targeting monoclonal antibodies (e.g., girentuximab) have been explored for diagnostic imaging and therapeutic applications in renal cancer, leveraging CA9's tumor-specific expression. Additionally, CA9 antibody-based assays are used to assess tumor hypoxia status, predict treatment responses, and monitor disease recurrence. Despite promising applications, challenges remain in optimizing antibody specificity and therapeutic efficacy across diverse cancer types. Overall, CA9 antibodies represent a vital bridge between understanding tumor biology and developing targeted cancer interventions.